Danske Bank A S Acquires Shares of 58,943 DaVita Inc. $DVA

Danske Bank A S bought a new stake in DaVita Inc. (NYSE:DVA) during the 2nd quarter, HoldingsChannel reports. The firm bought 58,943 shares of the company’s stock, valued at approximately $13,114,000.

Other institutional investors and hedge funds have also modified their holdings of the company. NewEdge Advisors LLC raised its position in shares of DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in DaVita by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company’s stock worth $27,403,000 after buying an additional 28,739 shares in the last quarter. Cerity Partners LLC raised its holdings in shares of DaVita by 7.0% during the second quarter. Cerity Partners LLC now owns 2,638 shares of the company’s stock valued at $376,000 after acquiring an additional 172 shares during the last quarter. Bank of Nova Scotia lifted its position in shares of DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company’s stock valued at $686,000 after acquiring an additional 176 shares in the last quarter. Finally, Natixis lifted its position in shares of DaVita by 80.9% in the second quarter. Natixis now owns 7,297 shares of the company’s stock valued at $1,039,000 after acquiring an additional 3,264 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider owned 109,194 shares of the company’s stock, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.90% of the stock is owned by corporate insiders.

DaVita Stock Performance

NYSE DVA opened at $175.54 on Friday. The stock’s fifty day moving average is $215.64 and its two-hundred day moving average is $181.58. The firm has a market capitalization of $11.20 billion, a P/E ratio of 14.36, a price-to-earnings-growth ratio of 0.59 and a beta of 0.88. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts forecast that DaVita Inc. will post 14.57 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DVA shares. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and raised their price objective for the company from $201.00 to $220.00 in a report on Friday, August 7th. Weiss Ratings upgraded shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 5th. Oppenheimer set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Barclays upped their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $221.75.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.